Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice

BACKGROUND: Although imatinib is a well-established first-line drug for treating a vast majority of gastrointestinal stromal tumours (GIST), GISTs acquire secondary resistance during therapy. Multi-omics approaches provide an integrated perspective to empower the development of personalised therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Macioszek, Szymon, Dudzik, Danuta, Bartoszewski, Rafał, Stokowy, Tomasz, Lambrechts, Diether, Boeckx, Bram, Wozniak, Agnieszka, Schöffski, Patrick, Markuszewski, Michał J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945753/
https://www.ncbi.nlm.nih.gov/pubmed/36774883
http://dx.doi.org/10.1016/j.tranon.2023.101632

Ejemplares similares

Ejemplares similares